8-K - Galectin Therapeutics Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Galectin Therapeutics Inc. appointed Dr. Henry Brem to its Board of Directors effective March 12, 2026. Dr. Brem, an internationally recognized neurosurgeon-scientist and Henry Brem Professor of Neurosurgery at Johns Hopkins University, brings extensive experience in translational medicine and clinical development to support the company's belapectin programs.

Key Takeaways

1Board appointed Dr. Henry Brem as independent director effective March 12, 2026

2Dr. Brem serves as Henry Brem Professor of Neurosurgery at Johns Hopkins University and Co-Director of the Brain Cancer Program at Sidney Kimmel Comprehensive Cancer Center

3Dr. Brem previously served as Director of Neurosurgery at Johns Hopkins from 2000 to 2025

4Compensation per Company’s standard non-employee director program; no initial committee service

5No arrangements or understandings with other persons; no reportable transactions under Item 404(a)

Current Report Details

Event Type

Management Change

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 12

Management Change

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated March 17, 2026 104 Cover Page Interactive Data File (embedded

Exhibits Only

Source Document

Executive & Director Changes

Dr. Henry Brem

independent director

appointed

Effective: 2026-03-12

Exhibits (2)

8-K

99.1

EXHIBIT 99.1